Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer (NCT02306954)
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer
🩺 Plain-English Summary (8th-Grade Level)
All patients will receive IL-2 (14 planned doses with an additional cycle 14 days after the first). Responding patients with regressing disease are eligible for up to 6 IL-2 cycles. Patients assigned to SBRT arm will receive two doses of SBRT on the Wednesday and Friday before the Monday on which IL-2 starts.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (10 items).
Location: Portland Providence Medical Center — Portland, Oregon
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- No metastatic site amenable to SBRT
- Patients with brain metastases not candidates for radiosurgery alone
- Previous radiation to sites proposed for SBRT
- Patients with active systemic, pulmonary, or pericardial infection
- Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus
- Evidence of ischemia on exercise tolerance test, stress thallium study, or baseline EKG
- Clinically significant underlying pulmonary disease as measured by pulmonary function tests
- Blood tests within protocol-specified range
- Need for chronic steroids
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Portland Providence Medical Center — Portland, Oregon
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
- 💵 Compensation indicated: All patients will receive IL-2 (14 planned doses with an additional cycle 14 days after the first).
More studies in Renal Cell Carcinoma
- Drug Screening Using Novel IMD in Renal Cell Carcinoma — Boston, Massachusetts
- Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations — Baltimore, Maryland
- Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) — Birmingham, Alabama
- Delving Into Participation Trends in Renal Cell Carcinoma Studies — San Francisco, California
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma — Birmingham, Alabama
- A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma — Basking Ridge, New Jersey
Explore by condition: All Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.